Molecular biology diagnosis with CRISPR-Cas
Article Sidebar
Main Article Content
Abstract
Since its inception, molecular biology has undergone continuous advancements, driven by the imperative to meet the evolving demands of clinical practice with increasing precision and efficiency.
The emergence of personalized therapies has further underscored the need for diagnostic methodologies that are not only rapid and accurate but also highly performant.
Within this framework, the bacterial defense mechanism known as CRISPR-Cas discovered relatively recently has demonstrated exceptional versatility in both clinical and diagnostic applications. Its remarkable potential has attracted the attention of numerous research groups worldwide, who are actively investigating its integration into molecular diagnostics.
A key distinguishing feature of CRISPR-Cas lies in its programmability to target specific nucleotide sequences, offering a level of specificity that surpasses traditional restriction enzymes.
This capability renders it particularly suitable for the diagnosis of human genetic disorders, mitochondrial DNA alterations, and the detection of pathogenic microorganisms.
Although its application in diagnostics remains relatively novel, current studies have yielded highly promising results, highlighting tangible advantages over conventional techniques.
Consequently, it is reasonable to anticipate that, with continued research and technical refinement, healthcare professionals will soon have access to innovative molecular biology approaches capable of rapidly identifying targeted pathologies.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., et al. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (New York, N.Y.), 337(6096), 816–821.
Bhatia, S., Pooja, & Yadav, S. K. (2023). CRISPR-Cas for genome editing: Classification, mechanism, designing and applications. International Journal of Biological Macromolecules, 238, 124054.
Jiang, F., & Doudna, J. A. (2015). The structural biology of CRISPR-Cas systems. Current Opi-nion in Structural Biology, 30, 100–111.
Koonin, E. v, Makarova, K. S., & Zhang, F. (2017). Diversity, classification and evolution of CRISPR-Cas systems. Current Opinion in Microbiology, 37, 67–78.
Fu, W., Ma, J., Wang, Z., Tang, N., et al. (2025). Mechanisms and engineering of a miniature type V-N CRISPR-Cas12 effector enzyme. Nature Communications, 16(1), 5667.
Bonini, A., Poma, N., Vivaldi, F., Kirchhain, A., et al. (2021). Advances in biosensing: The CRISPR/Cas system as a new powerful tool for the detection of nucleic acids. Journal of Pharmaceutical and Biomedical Analysis, 192, 113645.
Gootenberg, J. S., Abudayyeh, O. O., Kellner, M. J., et al. (2018). Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science, 360(6387), 439–444.
Mukama, O., Wu, J., Li, Z., Liang, Q., et al. (2020). An ultrasensitive and specific point-of-care CRISPR/Cas12 based lateral flow biosensor for the rapid detection of nucleic acids. Bio-sensors and Bioelectronics, 159, 112143.
Ai, J.-W., Zhou, X., Xu, T., Yang, M., et al. (2019). CRISPR-based rapid and ultra-sensitive dia-gnostic test for Mycobacterium tuberculosis. Emerging Microbes & Infections, 8(1), 1361–1369.
Chakraborty, J., Chaudhary, A. A., Khan, S.-U.-D., Rudayni, H. A., et al. (2022). CRISPR/Cas-Based Biosensor As a New Age Detection Method for Pathogenic Bacteria. ACS Omega, 7(44), 39562–39573.
Asano, K., Yoshimi, K., Takeshita, K., Mitsuhashi, S., et al. (2024). CRISPR Diagnostics for Quantification and Rapid Diagnosis of Myotonic Dystrophy Type 1 Repeat Expansion Disor-ders. ACS Synthetic Biology, 13(12), 3926–3935.
Xu, S., Shiomi, H., Yamashita, Y., Koyama, S., et al. (2024). CRISPR-Cas9-guided amplifica-tion-free genomic diagnosis for familial hypercholesterolemia using nanopore sequencing. PLOS ONE, 19(3), e0297231.
Kohabir, K. A. V., Nooi, L. O., Brink, A., Brakenhoff, R. H., et al. (2023). In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region. The CRISPR Journal, 6(2), 127–139.
Feng, Z., Kong, D., Jin, W., He, K., et al. (2023). Rapid detection of isocitrate dehydrogenase 1 mutation status in glioma based on Crispr-Cas12a. Scientific Reports, 13(1), 5748.
Qi, J., Qi, Q., Zhou, Z., Wu, Y., et al. (2024). PER-CRISPR/Cas14a system-based electrochemi-cal biosensor for the detection of ctDNA EGFR L858R. Analytical Methods, 16(1), 51–61.
Cao, G., Chen, X., Deng, Y., Nie, F., et al. (2021). Single-nucleotide variant of PIK3CA H1047R gene assay by CRISPR/Cas12a combined with rolling circle amplification. Analytica Chimica Acta, 1182, 338943.
Jiang, H., Duan, K., Han, X., Wang, J., et al. (2021). Detection of Mitochondrial Mutations Through Isothermal Nucleic Acid Amplification Coupled With Clustered Regularly Interspa-ced Short Palindromic Repeat-Associated Endonuclease Cas13a. Frontiers in Genetics, 11.